Patents by Inventor Roberto Gambari

Roberto Gambari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoxazole derivatives as inducers of fetal hemoglobin in erythroid precursor cells from beta-thalassemic patients
    Patent number: 11077116
    Abstract: The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in ?-thalassemia and sickle cell disease (SCD) patients.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 3, 2021
    Assignee: RARE PARTNERS SRL
    Inventors: Ilaria Lampronti, Roberto Gambari, Daniele Simoni
  • ISOXAZOLE DERIVATIVES AS INDUCERS OF FETAL HEMOGLOBIN IN ERYTHROID PRECURSOR CELLS FROM BETA-THALASSEMIC PATIENTS
    Publication number: 20200206234
    Abstract: The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in ?-thalassemia and sickle cell disease (SCD) patients.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 2, 2020
    Applicant: RARE PARTNERS SRL
    Inventors: Ilaria Lampronti, Roberto Gambari, Daniele Simoni
  • Diagnostic and therapeutic application of CTL and NK functionally selected cells
    Patent number: 9528981
    Abstract: The invention proposes a novel therapeutic and diagnostic methodology based on the use of effector cells (for example CTL and NK cells) selected for being able to induce lysis in target cells. In particular, the invention teaches how to select strains of effector cells of the immune system according to their lytic properties. It also teaches how diagnostic procedures for checking the activity of therapeutic vaccines can be improved with respect to what shown. Finally, it shows how cell therapies used at present can be improved by using this approach.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 27, 2016
    Assignee: Menarini Silicon Biosystems S.p.A.
    Inventors: Roberto Gambari, Roberto Guerrieri
  • Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC
    Patent number: 9371295
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 21, 2016
    Assignees: IRBM-SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Method of making and administering quinoline derivatives as anti-cancer agents
    Patent number: 9321730
    Abstract: The present invention relates methods of preparing quinoline derivative compounds, and administering such compounds in the treatment of solid and non-solid tumors, notably on liver cancer.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 26, 2016
    Assignee: The Hong Kong Polytechnic University
    Inventors: Albert Sun-chi Chan, Johnny Cheuk-on Tang, Kim-hung Lam, Chung-hin Chui, Stanton Hon-lung Kok, Sau Hing Chan, Filly Cheung, Roberto Gambari, Chor Hing Cheng
  • Trimethylangelicin as CFTR corrector in bronchial epithelial cells
    Patent number: 9283206
    Abstract: The invention relates to the use of 4,6,4?-trimethylangelicin (TMA) and structural analogs thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: March 15, 2016
    Assignees: Azienda Ospedaliera Universitaria Integrata di Verona, Universita' degli Studi di Ferrara, Universita' degli Studi di Bari, Rare Partners S.r.l.
    Inventors: Giulio Cabrini, Valeria Casavola, Roberto Gambari
  • TRIMETHYLANGELICIN AS CFTR CORRECTOR IN BRONCHIAL EPITHELIAL CELLS
    Publication number: 20150290167
    Abstract: The invention relates to the use of 4,6,4?-trimethylangelicin (TMA) and structural analogues thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508de1-CFTR mutation.
    Type: Application
    Filed: June 13, 2012
    Publication date: October 15, 2015
    Applicants: AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA DI VERONA, RARE PARTNERS S.R.L., UNIVERSITA' DEGLI STUDI DI BARI, UNIVERSITA' DEGLI STUDI DI FERRARA
    Inventors: Giulio Cabrini, Valeria Casavola, Roberto Gambari
  • COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC
    Publication number: 20150218112
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Application
    Filed: August 7, 2013
    Publication date: August 6, 2015
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Double-stranded synthetic oligonucleotides useful for inducing apoptosis of osteoclasts for the treatment of osteopenic pathologies
    Patent number: 7659258
    Abstract: The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the treatment of osteopenic diseases such as for example osteoporosis. The oligonucleotide according to the invention is characterized in that it comprises the sequence 5?-ATTTATTTTCAATACTGACT-3? (SEQ ID NO: 1) or a fragment or a mutant thereof.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: February 9, 2010
    Assignees: Universita' Degli Studi di Ferrara, Associazione Veneta per la Lotta Alla Talassemia
    Inventors: Roberto Gambari, Letizia Penolazzi, Roberta Piva
  • DIAGNOSTIC AND THERAPEUTIC APPLICATION OF CTL AND NK FUNCTIONALLY SELECTED CELLS
    Publication number: 20090325213
    Abstract: The invention proposes a novel therapeutic and diagnostic methodology based on the use of effector cells (for example CTL and NK cells) selected for being able to induce lysis in target cells. In particular, the invention teaches how to select strains of effector cells of the immune system according to their lytic properties. It also teaches how diagnostic procedures for checking the activity of therapeutic vaccines can be improved with respect to what shown. Finally, it shows how cell therapies used at present can be improved by using this approach.
    Type: Application
    Filed: April 12, 2007
    Publication date: December 31, 2009
    Inventors: Roberto Gambari, Roberto Guerrieri
  • Use of angelicin and of its structural analogues for the treatment of thalassemia
    Patent number: 7572827
    Abstract: The use of angelicin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. A structural analogue which is particularly preferred for this purpose is bergapten.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: August 11, 2009
    Assignees: Universita' Degli Studi Di Ferrara, Associazione Veneta Per La Lotta Alla Talassemia
    Inventors: Nicoletta Bianchi, Monica Borgatti, Roberto Gambari, Ilaria Lampronti
  • Use of rapamycin and structural analogues thereof
    Patent number: 7541380
    Abstract: The use of rapamycin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: June 2, 2009
    Assignees: Universita' Degli Studi do Ferrara, Associazione Veneta per la Lotta Alla Talassemia
    Inventors: Nicoletta Bianchi, Monica Borgatti, Roberto Gambari, Carlo Mischiati
  • Method of making and administering quinoline derivatives as anti-cancer agents
    Publication number: 20090054482
    Abstract: The present invention relates methods of preparing quinoline derivative compounds, and administering such compounds in the treatment of solid and non-solid tumors, notably on liver cancer.
    Type: Application
    Filed: August 21, 2007
    Publication date: February 26, 2009
    Applicant: The Hong Kong Polytechnic University
    Inventors: Albert Sun-chi Chan, Johnny Cheuk-on Tang, Kim-hung Lam, Chung-hin Chui, Stanton Hon-lung Kok, Sau Hing Chan, Filly Cheung, Roberto Gambari, Chor Hing Cheng
  • Double-Stranded Synthetic Oligonucleotides Useful For Inducing Apoptosis of Osteoclasts For the Treatment of Osteopenic Pathologies
    Publication number: 20080171717
    Abstract: The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the treatment of osteopenic diseases such as for example osteoporosis. The oligonucleotide according to the invention is characterised in that it comprises the sequence 5?-ATTTATTTTCAATACTGACT-3? or a fragment or a mutant thereof.
    Type: Application
    Filed: March 30, 2006
    Publication date: July 17, 2008
    Applicants: UNIVERSITA' DEGLI STUDI DI FERRARA, ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIA
    Inventors: Roberto Gambari, Letizia Penolazzi, Roberta Piva
  • Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of ?-thalassaemia
    Patent number: 7396851
    Abstract: The invention relates to the use of structural analogues of distamycin having the general formula (I), (II), (III), (IV) or (V) or their pharmaceutically acceptable salts, for the preparation of a medicament for the therapeutic treatment of ?-thalassaemia.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: July 8, 2008
    Assignees: Universita' Degli Studi Di Ferrara, Associazione Veneta per La Lotta Alla Talassemia, Associazione per La Lotta Alla Talassemia Di Ferrara
    Inventors: Pier Giovanni Baraldi, Nicoletta Bianchi, Giordana Feriotto, Roberto Gambari, Carlo Mischiati, Romeo Romagnoli
  • Synthetic oligonucleotides as inducers of erythroid differentiation
    Patent number: 7262175
    Abstract: The invention refers to a synthetic double-stranded oligonucleotide having a length comprised between 10 and 50 bases and a nucleic acid sequence selected from the group consisting of: (a) sequences corresponding to a selected portion of the promoter of human ?-globin gene; and (b) sequences corresponding to a selected portion of the human genomic region comprised between the ?-globin gene and the ??-cluster, for use as an inducer of erythroid differentiation.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: August 28, 2007
    Assignees: Universita' Degli Studi Di Ferrara, Associazione Veneta Per La Lotta Alla Talassemia, Associazione Per La Lotta Alla Talassemia Di Ferrara, Chiesi Farmaceutici S.p.A.
    Inventors: Nicoletta Bianchi, Giordana Feriotto, Roberto Gambari, Carlo Mischiati
  • Novel Use of rapamycin and structural analogues thereof
    Publication number: 20060154950
    Abstract: The use of rapamycin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described.
    Type: Application
    Filed: July 3, 2003
    Publication date: July 13, 2006
    Applicants: ITA' DEGLI STUDI DI FERRARA, ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIA
    Inventors: Nicoletta Bianchi, Monica Borgatti, Roberto Gambari, Carlo Mischiati
  • Use of angelicin and of its structural analogues for the treatment of thalassemia
    Publication number: 20060111433
    Abstract: The use of angelicin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. A structural analogue which is particularly preferred for this purpose is bergapten.
    Type: Application
    Filed: July 30, 2003
    Publication date: May 25, 2006
    Inventors: Nicoletta Bianchi, Monica Borgatti, Roberto Gambari, Ilaria Lampronti
  • Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia
    Publication number: 20040259799
    Abstract: The invention relates to the use of structural analogues of distamycin having the general formula (I), (II), (III), (IV) or (V) or their pharmaceutically acceptable salts, for the preparation of a medicament for the therapeutic treatment of &bgr;-thalassaemia.
    Type: Application
    Filed: August 13, 2004
    Publication date: December 23, 2004
    Inventors: Pier Giovanni Baraldi, Nicoletta Bianchi, Giordana Feriotto, Roberto Gambari, Carlo Mischiati, Romeo Romagnoli
  • Synthetic oligonucleotides as inducers of erythroid differentiation
    Publication number: 20030073660
    Abstract: The invention refers to a synthetic double-stranded oligonucleotide having a length comprised between 10 and 50 bases and a nucleic acid sequence selected from the group consisting of: (a) sequences corresponding to a selected portion of the promoter of human &ggr;-globin gene; and (b) sequences corresponding to a selected portion of the human genomic region comprised between the &ggr;-globin gene and the &dgr;&bgr;-cluster, for use as an inducer of erythroid differentiation.
    Type: Application
    Filed: September 13, 2002
    Publication date: April 17, 2003
    Inventors: Nicoletta Bianchi, Giordana Feriotto, Roberto Gambari, Carlo Mischiati